Tsingke Biotech and iGeneTech Join Forces to Revolutionize Synthetic Biology

Tsingke Biotech and iGeneTech team up to accelerate gene synthesis and unlock new possibilities in biotech sector and beyond.

Beijing Tsingke Biotech Co., Ltd. and iGeneTech Bioscience Co., Ltd. have announced that both the firms will be form a strategic partnership, which aims at advancing the synthetic biology sector. This collaboration will bring together the strengths of both companies to drive innovation, simplify product development, and expand market reach.

In recent times, synthetic biology has been gaining more popularity and is evolving as a transformative force with wide range of applications, which include precision medicine, bio-breeding, and gene editing. At the core of these advancements are high-throughput and column-based synthesis, which Tsingke Biotech and iGeneTech aim to further develop.

Tsingke Biotech, a leader in gene synthesis, has developed a fully integrated industrial chain that spans raw materials, equipment, process design, AI, and digital technologies. The company well known for its stability and scalability offers state-of-the-art column synthesis and factory-driven production system that supports production from small-scale laboratory production runs (2nmol) to large-scale industrial synthesis (12mmol).

On the other hand, iGeneTech contributes its proprietary Ignite 3.0 high-throughput synthesis platform. With its ability to process oligo pools this platform addresses key challenges around throughput, speed, and cost.

Now, this partnership will help both the companies develop a robust integrated system that spans the entire spectrum from "synthesis" to "application," primarily focusing on innovation, sustainability, and precision to meet the needs of a rapidly evolving biotechnology market.